89bio to participate in the leerink partners global biopharma conference

San francisco, march 05, 2024 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will participate in a fireside chat at the leerink partners global biopharma conference on tuesday, march 12, 2024 at 1:40 pm est and participate in one-on-one investor meetings.
ETNB Ratings Summary
ETNB Quant Ranking